Canadian clinical stage pharmaceutical company with offices in Toronto, founded in 2019 as Cybin and renamed Helus Pharma in January 2026. Develops synthetic molecules that act on serotonin pathways and are intended to promote neuroplasticity, with its lead candidate in late stage trials as an add-on treatment for major depressive disorder, and works on further candidates for anxiety and other mental health conditions.
Aucun commentaire disponible.
Laissez votre note & commentaire